Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts. Show more

Location: 890 Winter Street, Waltham, MA, 02451, United States | Website: https://upstreambio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.078B

52 Wk Range

$5.14 - $29.46

Previous Close

$20.00

Open

$20.01

Volume

563,550

Day Range

$18.57 - $20.28

Enterprise Value

686.2M

Cash

393.6M

Avg Qtr Burn

-28.49M

Insider Ownership

14.81%

Institutional Own.

90.42%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.